UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  FORM 12b-25

                          NOTIFICATION OF LATE FILING

     [  ] Form 10-K  [  ]Form 20-F  [  ]Form 11-K  [X] Form 10-Q  [ ] Form 10-D
     [  ] Form N-SAR  [ ] Form N-CSR

     For Period Ended:  October 31, 2009

[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended: ___________________

    Nothing in this form shall be construed to imply that the Commission has
    ------------------------------------------------------------------------
                   verified any information contained herein.
                   ------------------------------------------


PART I -- REGISTRANT INFORMATION
Full Name of Registrant: Lightlake Therapeutics Inc.
-----------------------------------------------
Former Name if Applicable: Madrona Ventures Inc.
--------------------------------------------------------------------------------
Address of Principal Executive Office(Street and Number):54 Baker Street., 6th
------------------------------------------------------------------------------
Floor
-----

City, State and Zip Code: London, England, W1U 7BU
---------------------------------------------------------------------


<PAGE>

PART II -- RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)


          (a)  The reasons described in reasonable detail in Part III of
               this form could not be eliminated without unreasonable effort or
               expense;

[X]       (b)  The subject annual report, semi-annual report, transition
               report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form
               N-CSR, or portion thereof, will be filed on or before the
               fifteenth calendar day following the prescribed due date; or the
               subject quarterly report or transition report on Form 10-Q, or
               subject distribution report on Form 10-D, or portion thereof will
               be filed on or before the fifth calendar day following the
               prescribed due date; and

          (c)  The accountant's statement or other exhibit required by Rule
               12b-25(c) has been attached if applicable.


<PAGE>

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
10-D, N-SAR, N-CSR, or the transition report portion thereof, could not be filed
within the prescribed time period.

The Registrant requests an extension for the filing of its Quarterly Report on
Form 10-Q for the three-month period ended October 31, 2009.  The Registrant
needs additional time to complete the preparation of the Form 10-Q, in
particular, the Registrant's financial statements and the disclosure on the
Registrant's management's discussion and analysis.  The Registrant plans to file
the Form 10-Q as soon as reasonably practicable.


PART IV-- OTHER INFORMATION

(1)
Name and telephone number of person to contact in regard to this notification



        Seijin Ki                416                  833-8542
        ---------                ---                  --------
        (Name)               (Area Code)           (Telephone Number)

(2)
     Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed?  If answer is no,
identify report(s).     [X] Yes  [ ] No

(3)
     Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?  
[ ] Yes  [ X ] No

If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.


<PAGE>

                          Lightlake Therapeutics, Inc.
                          ----------------------------
                  (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.

Date:  December 16, 2009

                                     By: /s/ Seijin Ki
                                     -----------------
                                         Seijin Ki
                                         Chief Financial Officer and Secretary